{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"ORR is presented in this outcome measure as number of responders. Responders were those who had complete response, stringent complete response, very good partial response, partial response. International Uniform Response Criteria for Multiple Myeloma (Durie et al., 2006). was used for assessment of tumors.Tumor types evaluated include Multiple Myeloma (MM).","groups":[{"description":"Participants with MM who received study drug in part 2.","id":"OG000","title":"Part 2: Multiple Myeloma (MM)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full analysis set included all participants who received at least 1 dose of study treatment. \"Number of Participants Analyzed\" refers to participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)","title":"Part 2: Overall Response Rate (ORR)- Durie 2006- Disease Indication","type":"SECONDARY","unitOfMeasure":"Participants"}